53803 Early and Sustained Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Participants with Moderate-to-Severe Scaling or Plaque Elevation
Recommended Citation
Stein-Gold L, Tanghetti E, Lain E, Murina A, Jacobson A. 53803 Early and Sustained Efficacy of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion in Participants with Moderate-to-Severe Scaling or Plaque Elevation. J Am Acad Dermatol 2024; 91(3):AB189.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Background: Hyperkeratotic psoriasis produces plaques with extensive elevation and scaling and may be challenging to treat. Tazarotene-induced gene modulation may normalize the keratinocyte differentiation observed in psoriasis. This post hoc analysis of two phase 3 trials of fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) reports skin clearance as measured by the product of the Investigator’s Global Assessment and affected body surface area (IGA×BSA) in participants with moderate-to-severe scaling or plaque elevation. Methods: Participants were randomized to once-daily HP/TAZ or vehicle lotion and evaluated at weeks 2 through 8 with post-treatment follow-up at week 12. Moderate-to-severe elevation or scaling was defined as baseline target plaque score of 3 (moderate) or 4 (severe) on a 0-to-4 scale. Outcomes included rate of ≥75% improvement from baseline in IGA×BSA (IGA×BSA-75; correlates with ≥75% improvement in the Psoriasis Area and Severity Index) and percent change from baseline in IGA×BSA. Results: Participants with moderate-to-severe scaling receiving HP/TAZ (N=240) achieved significantly greater rates of IGA×BSA-75 compared with vehicle (N=120), starting at week 2 (P=0.019) and sustained through week 12 (P<0.001). Additionally, significant improvements in percent change in IGA×BSA from baseline were observed as early as week 2 through week 12 (P<0.001, all time points). Similar significant improvements were observed in participants with moderate-to-severe plaque elevation receiving HP/TAZ (N=246) compared with vehicle (N=128). Conclusions: HP/TAZ was associated with clinically meaningful, early, and sustained skin clearance in participants with hyperkeratotic psoriasis, as defined by moderate to severe scaling or plaque elevation, which is often difficult to treat.
Volume
91
Issue
3
First Page
AB189
